Harpoon Therapeutics Inc HARP

NAS: HARP | ISIN: US41358P1066   8/03/2024
23,01 USD (+0,09%)
(+0,09%)   8/03/2024

6 februari 2024 · INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, HARP, FGH, PGTI · Persbericht

25 oktober 2023 · Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance? · Persbericht

24 oktober 2023 · Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance? · Persbericht

23 oktober 2023 · Thinking about buying stock in Sterling Infrastructure, Mereo BioPharma Group, RVL Pharmaceuticals, SeaStar Medical Holding, or Harpoon Therapeutics? · Persbericht

10 juli 2023 · Replicate Bioscience Appoints Rachael Lester as Chief Business Officer · Persbericht

11 maart 2021 · Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 · Persbericht

10 maart 2021 · Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update · Persbericht

9 maart 2021 · Harpoon Therapeutics to Participate in 33rd Annual Roth Conference · Persbericht

17 februari 2021 · Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference · Persbericht

13 januari 2021 · Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma · Persbericht

11 januari 2021 · Harpoon Therapeutics Announces Closing of Public Offering of Common Stock · Persbericht

7 januari 2021 · Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock · Persbericht

6 januari 2021 · Harpoon Therapeutics Announces Proposed Public Offering of Common Stock · Persbericht

4 januari 2021 · Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors · Persbericht

Mijn selecties